All In Biotech

Drug Trial Radar · NCT07753850

A Study of SL-325 in Crohn's Disease Patients

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SL-325 in Participants With Moderately to Severely Active Crohn's Disease

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 232 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

232

Planned (sponsor's estimate)

Start

Nov 9, 2026

Primary completion

Jul 2028

Study completion Jun 2030

Sponsor

Lead sponsor
Shattuck Labs, Inc.Industry
Sponsor type
Industry
First posted
Aug 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the efficacy of SL-325 in adult participants with moderate to severely active Crohn's disease. The study consists of a screening period of up to 6 weeks, a 12-week induction period, 38-week maintenance period, 52-week long-term extension period, and a 10-week follow-up period.

Conditions

  • Crohn's Disease

Interventions

  • SL-325Drug

    SL-325 administered intravenously

  • PlaceboDrug

    Placebo administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants who achieve endoscopic responseTime frame: Week 12

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Little Rock, Arkansas · Not yet recruiting

  • Clinical Trial Site

    Oxnard, California · Not yet recruiting

  • Clinical Trial Site

    Temple City, California · Not yet recruiting

  • Clinical Trial Site

    West Hills, California · Not yet recruiting

  • Clinical Trial Site

    Inverness, Florida · Not yet recruiting

  • Clinical Trial Site

    Kissimmee, Florida · Recruiting

  • Clinical Trial Site

    Naples, Florida · Not yet recruiting

  • Clinical Trial Site

    Orlando, Florida · Not yet recruiting

  • Clinical Trial Site

    Tampa, Florida · Not yet recruiting

  • Clinical Trial Site

    Kansas City, Kansas · Not yet recruiting

  • Clinical Trial Site

    Houma, Louisiana · Recruiting

  • Clinical Trial Site

    Marrero, Louisiana · Not yet recruiting

  • Clinical Trial Site

    Glen Burnie, Maryland · Not yet recruiting

  • Clinical Trial Site

    Boston, Massachusetts · Not yet recruiting

  • Clinical Trial Site

    Liberty, Missouri · Not yet recruiting

  • Clinical Trial Site

    St Louis, Missouri · Not yet recruiting

  • Clinical Trial Site

    Maspeth, New York · Not yet recruiting

  • Clinical Trial Site

    Cincinnati, Ohio · Not yet recruiting

  • Clinical Trial Site

    Columbus, Ohio · Not yet recruiting

  • Clinical Trial Site

    Nashville, Tennessee · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.